BioClinica®, Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced that TauRx Therapeutics has signed agreements with BioClinica to use Trident IWR/IVR and Imaging Core Lab (ICL) solutions to support its upcoming Phase III clinical trials. TauRx, a Singapore-based company, focuses its research on therapies and diagnostics for the treatment of Alzheimer's disease and other neurodegenerative disorders. With primary research facilities in Aberdeen in the United Kingdom, TauRx is the latest European customer to select BioClinica for both Imaging and eClinical offerings.
TauRx has selected Trident IWR/IVR for a series of expanded trials for its pipeline of neurology treatment candidates. “TauRx chose Trident IWR to reduce the lead time and effort needed to prepare for our studies, while supporting all of our randomization and clinical supplies tracking requirements,” said Dr. Jiri Hardlund, Chief Medical Officer for TauRx. “When we investigated the available technologies, it was clear that Trident offered clear advantages for our trials’ requirements.”
A separate selection team evaluated imaging solutions, and also selected BioClinica for its Imaging Core Lab solutions for processing MRI data. “MRI imaging represents a critical eligibility and safety component of our clinical studies,” said Dr. Diane Downie, Global Logistics and Support Lead at TauRx. “Our MRI imaging partner needed to understand the unique requirements of our pioneering scientific research. BioClinica’s MRI imaging solution best matched all of our requirements.”
BioClinica’s Imaging Core Lab uses innovative technology to efficiently acquire, process, and read medical images. With more than 22 years of world-wide experience, the team brings the scientific knowledge to make that technology work for sponsors of any size. With a highly-regarded medical affairs team and deep roster of collaborative consultants, BioClinica provides the imaging expertise necessary to ensure the highest quality clinical trial outcomes.
"BioClinica is clearly a technology leader for clinical trial applications,” said Peter Benton, BioClinica's eClinical Solutions President. “While great technology is essential, our business model also offers a fresh approach for clinical trial support -- one that makes it faster and more cost-efficient than other alternatives, whether the sponsor is large or small. Combined with our global reach, experience and customer support, we believe no other solution matches BioClinica for value or performance.”
TauRx Therapeutics is a clinical stage pharmaceutical company focused on the discovery of Tau Protein Aggregation Inhibitors and other novel therapies and diagnostics for the treatment of Alzheimer's disease (AD) and other neurodegenerative disorders. TauRx is developing drugs to treat the underlying pathology of AD, to modify or halt disease progression or to prevent it entirely. TauRx Therapeutics is headquartered in Singapore with primary research facilities in Aberdeen, Scotland. For more information please visit http://www.taurx.com.
About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 22 years of experience and more than 2,500 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.
Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company’s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control.The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.